Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 13Carcinoma, Ovarian Epithelial 8Fallopian Tube Neoplasms 6Peritoneal Neoplasms 1Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 5Cisplatin 4Paclitaxel 3lenvatinib 2Fluorouracil 2trastuzumab deruxtecan 1sargramostim 1resiquimod 1poly ICLC 1oregovomab 1liposomal doxorubicin 1fluoroazomycin arabinoside 1fludarabine 1cemiplimab 1catumaxomab 1cabozantinib 1Therapeutics 1Therapeutic Irrigation 1TKM-080301 1Radiation, Ionizing 1Radiation 1Quality of Life 1Proctoscopy 1Prednisone 1Prednisolone 1Patient Reported Outcome Measures 1Papanicolaou Test 1Oxaliplatin 1Nelfinavir 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × oregovomab × Gynecologic × Clear all
NCT01616303 2020-09-14

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

Quest PharmaTech Inc.

Phase 2 Completed
97 enrolled
Gynecologic

Adenocarcinoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡